Gut microbial metabolite butyrate protects against proteinuric kidney disease through epigenetic- and GPR109a-mediated mechanisms.
Animals
Bacteria
/ metabolism
Butyrates
/ metabolism
Cells, Cultured
Epigenesis, Genetic
Gastrointestinal Microbiome
/ physiology
Kidney Diseases
/ prevention & control
Male
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Knockout
Podocytes
/ drug effects
Protective Agents
/ metabolism
Proteinuria
/ prevention & control
Receptors, G-Protein-Coupled
/ genetics
ADR nephropathy
SCFA
glomerulopathy
podocyte
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
pubmed:
2
8
2019
medline:
9
6
2020
entrez:
2
8
2019
Statut:
ppublish
Résumé
Butyrate is a short-chain fatty acid derived from the metabolism of indigestible carbohydrates by the gut microbiota. Butyrate contributes to gut homeostasis, but it may also control inflammatory responses and host physiology in other tissues. Butyrate inhibits histone deacetylases, thereby affecting gene transcription, and also signals through the metabolite-sensing G protein receptor (GPR)109a. We produced an mAb to mouse GPR109a and found high expression on podocytes in the kidney. Wild-type and
Identifiants
pubmed: 31366236
doi: 10.1096/fj.201901080R
doi:
Substances chimiques
Butyrates
0
Hcar2 protein, mouse
0
Protective Agents
0
Receptors, G-Protein-Coupled
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM